Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aura Biosciences, Inc.AURA · Entity 5142 | Chief Technology Officer | March 02, 2026 | March 03, 2026 |
| FATE THERAPEUTICS INCFATE · Entity 5968 | Chief Technical Officer | January 10, 2023 | January 11, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aura Biosciences, Inc.
Report date March 02, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 243,736 |
Reported balance
After 2026-03-02 transaction · row 1
1 source rowRow 1 · 2026-03-02 · Grant · Acquired 62,339 · Balance 243,736 F1: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on January 15, 2027, subject to the Reporting Person's continued service as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.14 · Expires 2036-03-02 | Direct | 112,661 |
Reported balance
After 2026-03-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-02 · Grant · Acquired 112,661 · Balance 112,661 F2: The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on January 15, 2027, subject to the Reporting Person's continued service as of each such vesting date.
F2: The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.
FATE THERAPEUTICS INC
Report date January 10, 2023 · Filed January 11, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 123,705 |
Reported balance
After 2023-01-10 transaction · row 1
1 source rowRow 1 · 2023-01-10 · Sale · Disposed 3,418 · Balance 123,705 F1: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 8,325 shares of Common Stock underlying restricted stock units granted to the Reporting Person on January 25, 2022. This sale was made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2: Represents the weighted average sale price of the shares sold from $5.12 to $5.37 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of he Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 8,325 shares of Common Stock underlying restricted stock units granted to the Reporting Person on January 25, 2022. This sale was made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
F2: Represents the weighted average sale price of the shares sold from $5.12 to $5.37 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of he Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2026 Filed Mar 3, 2026 21:05 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantStock Option (Right to Buy) · Derivative | 112,661 | $0.00 Strike: $6.14 | $0.00 |
DisclosureSEC source: 0001193125-26-088158 · ownership.xml · derivative · entry 2 Plavsic Mark · CIK 0001868719 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,661 Underlying: Common Stock · 112,661 shares Expires 2036-03-02 F2 · derivative.exercise_date: The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:05 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantCommon Stock | 62,339 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-088158 · ownership.xml · nonDerivative · entry 1 Plavsic Mark · CIK 0001868719 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 243,736 F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on January 15, 2027, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 00:47 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | SaleCommon Stock | 15,890 | $5.05 | $80,244.50 |
DisclosureSEC source: 0001193125-26-055497 · ownership.xml · nonDerivative · entry 1 Plavsic Mark · CIK 0001868719 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,397 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.04 to $5.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 16, 2025 Filed Oct 16, 2025 21:44 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | SaleCommon Stock | 12,169 | $6.35 | $77,273.15 |
DisclosureSEC source: 0001193125-25-241622 · ownership.xml · nonDerivative · entry 1 Plavsic Mark · CIK 0001868719 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 197,287 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 00:31 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | SaleCommon Stock | 2,151 | $7.75 | $16,670.25 |
DisclosureSEC source: 0000950170-25-022655 · ownership.xml · nonDerivative · entry 1 Plavsic Mark · CIK 0001868719 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,456 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 22:52 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantStock Option (Right to Buy) · Derivative | 59,525 | $0.00 Strike: $7.68 | $0.00 |
DisclosureSEC source: 0000950170-25-013829 · ownership.xml · derivative · entry 2 Plavsic Mark · CIK 0001868719 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,525 Underlying: Common Stock · 59,525 shares Expires 2035-02-02 F2 · derivative.exercise_date: The shares underlying this option vest as follows: 25% of the shares vest on February 3, 2026 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 22:52 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantCommon Stock | 90,475 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-013829 · ownership.xml · nonDerivative · entry 1 Plavsic Mark · CIK 0001868719 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 211,607 F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on February 15, 2026, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| October 16, 2024 Filed Oct 17, 2024 01:25 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | SaleCommon Stock | 7,383 | $9.85 | $72,722.55 |
DisclosureSEC source: 0000950170-24-115150 · ownership.xml · nonDerivative · entry 1 Plavsic Mark · CIK 0001868719 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,132 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| January 10, 2023 Filed Jan 11, 2023 21:07 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 3,418 | $5.24 | $17,910.32 |
DisclosureSEC source: 0001209191-23-002976 · doc4.xml · nonDerivative · entry 1 Plavsic Mark · CIK 0001868719 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,705 F1 · kind: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 8,325 shares of Common Stock underlying restricted stock units granted to the Reporting Person on January 25, 2022. This sale was made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: Represents the weighted average sale price of the shares sold from $5.12 to $5.37 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of he Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 05, 2022 Filed Jul 6, 2022 20:04 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 3,719 | $24.61 | $91,524.59 |
DisclosureSEC source: 0001209191-22-041053 · doc4.xml · nonDerivative · entry 1 Plavsic Mark · CIK 0001868719 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,123 F1 · kind: Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 9,500 shares of Common Stock underlying restricted stock units granted to the Reporting Person on June 14, 2021. This sale was made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: Represents the weighted average sale price of the shares sold from $24.34 to $24.82 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of he Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 21:37 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 53,058 | $0.00 Strike: $39.87 | $0.00 |
DisclosureSEC source: 0000899243-22-003447 · doc4.xml · derivative · entry 2 Plavsic Mark · CIK 0001868719 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,058 Underlying: Common Stock · 53,058 shares Expires 2032-01-24 F2 · derivative.exercise_date: The shares subject to this option vest in 48 equal month installments beginning on February 1, 2022 such that this option will be fully exercisable on January 1, 2026, subject to the Reporting Person's continued service with the Issuer as of each such date. Read SEC document |
| January 25, 2022 Filed Jan 27, 2022 21:37 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantCommon Stock | 33,302 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-003447 · doc4.xml · nonDerivative · entry 1 Plavsic Mark · CIK 0001868719 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,842 F1 · security: Award of restricted stock units that vest with respect to 1/4th of the underlying shares on each of January 8, 2023, January 8, 2024, January 8, 2025 and January 8, 2026, subject to the Reporting Person's continued service with the Issuer as of each such date. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 22:41 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantCommon Stock | 59,540 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-066162 · doc4.xml · nonDerivative · entry 1 Plavsic Mark · CIK 0001868719 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,540 F1 · kind: These shares were granted pursuant to a performance-based restricted stock unit award. The units will vest in three approximately equal installments conditioned upon the achievement, on or before December 31, 2026, of up to three specified late-stage clinical and regulatory milestones of the issuer, so long as the reporting person continues to serve as an employee of the issuer through each milestone achievement. Read SEC document |
| June 14, 2021 Filed Jun 22, 2021 20:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 18,500 | $0.00 Strike: $89.97 | $0.00 |
DisclosureSEC source: 0001209191-21-042373 · doc4.xml · derivative · entry 2 Plavsic Mark · CIK 0001868719 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2031-06-14 F2 · derivative.exercise_date: The option shall vest as to 25% of the underlying shares on June 14, 2022 and thereafter on a monthly basis for 36 additional months, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date. Read SEC document |
| June 14, 2021 Filed Jun 22, 2021 20:03 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantCommon Stock | 38,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-042373 · doc4.xml · nonDerivative · entry 1 Plavsic Mark · CIK 0001868719 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,000 F1 · kind: Exempt grant of restricted stock units pursuant to the Issuer's Inducement Equity Plan. The units will vest in four annual installments after July 1, 2021, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.